| " A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer" |
Completed |
LEE011 (Ribociclib) |
3 |
CLEE011E2301 |
KKUH , KFSH & RC-R , NGHA-R , NGHA-J |
| Multicenter, open-label, study to evaluate safety,tolerability, pharmacokinetics and, pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction) |
Completed |
Entresto |
3 |
CLCZ696B2319 |
KFSH&RC-R , KFSH-D |
| A Retrospective Observational Non-Interventional Study (NIS) to assess Patient Characteristics and Healthcare Resource Use (HCRU) among COVID-19 Patients Receiving Treatment with Nirmatrelvir; Ritonavir (PAXLOVIDTM) in the Kingdom of Saudi Arabia (KSA) |
Ongoing |
Paxlovid |
4 |
C4671054 |
King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah) , King Abdulaziz Medical City NG (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
| Stroke and High-risk TIAs Outcomes with Reduction of Treatment duration in Emergency Rooms. (SHORTER-Study). |
Ongoing |
PLAVIX Clopidogrel 75 MG TABLET |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah) |
| A Phase 3, Prospective, Multicenter, Double-blind, Double-dummy, Randomized, Active controlled, Parallel-group, Group-sequential, Adaptive, Event-driven Study to Compare Efficacy, Safety, and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension, Followed by an Open-label Treatment Period With Macitentan 75 mg. (UNISUS) |
Ongoing |
Macitentan |
3 |
AC-055-315 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Medical City (Riyadh) |
| AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY ≤2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS |
Ongoing |
Marstacimab |
3 |
B7841008 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam) |
| Non-Interventional Study of the Change in Joint Health in Adult Patients with Haemophilia A after Switching to Prophylaxis with Turoctocog Alfa Pegol (N8-GP) |
Ongoing |
Turoctocog Alfa Pegol (N8-GP) |
4 |
NN7088-492 |
King Abdulaziz University Hospital (Jeddah),King Fahad Hospital (Jeddah) |
| The Efficacy and Safety of Degludec Use for Glycemic Control in Critically Ill Patients: A Prospective Interventional Study |
Ongoing |
INSULIN ASPART,INSULIN DEGLUDEC |
3 |
1 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Assessment of Quality of Life in Patients with Relapsing Multiple Sclerosis treated with Cladribine tablets in the Kingdom of Saudi Arabia |
Ongoing |
Cladribine |
4 |
MS700568-2 |
King Fahad Medical City (Riyadh),King Saud Medical City (Riyadh),King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Faisal Specialist Hospital and Research Center (Jeddah),Dallah Hospital (Riyadh),King Fahd Armed Forces Hospital (Jeddah),King Fahd Military Medical Complex (Dhahran), Prince Sultan Military Medical City (Riyadh) |
| Medical treatment for congenital hereditary endothelial dystrophy |
Ongoing |
Nepafenac |
2 |
22071-CT |
King Khaled Eye Specialist Hospital (Riyadh) |
